Nektar Therapeutics Stock Price, News & Analysis (NASDAQ:NKTR)

$83.45 +0.02 (+0.02 %)
(As of 02/21/2018 02:25 PM ET)
Previous Close$83.45
Today's Range$82.90 - $87.45
52-Week Range$12.50 - $99.02
Volume2.38 million shs
Average Volume2.84 million shs
Market Capitalization$13.38 billion
P/E Ratio-115.90
Dividend YieldN/A
Beta2.04

About Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics logoNektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:NKTR
CUSIP64026810
Phone415-482-5300

Debt

Debt-to-Equity Ratio2.91%
Current Ratio4.14%
Quick Ratio3.99%

Price-To-Earnings

Trailing P/E Ratio-115.902777777778
Forward P/E Ratio-109.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$165.44 million
Price / Sales80.90
Cash FlowN/A
Price / CashN/A
Book Value$0.58 per share
Price / Book143.88

Profitability

Trailing EPS($0.72)
Net Income$-153,520,000.00
Net Margins-42.08%
Return on Equity-190.68%
Return on Assets-19.50%

Miscellaneous

Employees468
Outstanding Shares160,390,000

Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) posted its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.21 by $0.16. The biopharmaceutical company earned $152.90 million during the quarter, compared to the consensus estimate of $126.50 million. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The firm's quarterly revenue was up 321.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.32) earnings per share. View Nektar Therapeutics' Earnings History.

When will Nektar Therapeutics make its next earnings announcement?

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Nektar Therapeutics.

Where is Nektar Therapeutics' stock going? Where will Nektar Therapeutics' stock price be in 2018?

13 analysts have issued 1-year price targets for Nektar Therapeutics' shares. Their predictions range from $20.00 to $89.00. On average, they anticipate Nektar Therapeutics' stock price to reach $48.18 in the next year. View Analyst Ratings for Nektar Therapeutics.

What are Wall Street analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:

  • 1. According to Zacks Investment Research, "Nektar has a promising pipeline, with several updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone payment plus royalties for Movantik under the license agreement with AstraZeneca. Also, its recent codevelopment deal with Lilly for NKTR-358 is encouraging. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company, while disappointing products sales could leave an adverse impact on its financial results. Moreover, competition from various pharmaceutical and biotechnology companies is another matter of concern. Shares of the company have significantly outperformed the industry in the last one year." (2/21/2018)
  • 2. Mizuho analysts commented, "We expect both Nektar and BMY to jointly report clinical data going forward." (2/14/2018)
  • 3. BTIG Research analysts commented, "Nektar announced positive results from the Phase 3 SUMMIT-07 study of NKTR-181, its novel, proprietary, abuse-resistant opioid for pain. NKTR- 181 met all important primary and secondary efficacy endpoints in the 610- patient study, and the molecule appeared well tolerated, materially derisking the program. At its primary endpoint at week 12 postrandomization, average pain scores increased 1.46 points on the Numeric Rating Scale with placebo, vs. 0.92 points for NKTR-181 (p=0.0019); other secondary endpoints were also as positive. NKTR-181 has been FastTracked, a rarity for an opioid, and with this highly positive study in hand, there is a possibility for rapid progression of NKTR-181, and a material partnership. With 181's success, and with the potential for additional meaningful catalysts near-term, we raise our NKTR price target to $27." (3/21/2017)
  • 4. Jefferies Group LLC analysts commented, "The unexpected Ph 3 success for '181 brings this once very promising mu-opioid analgesic asset back to life. In our view, it could become NKTR's largest and most profitable product as it squarely addresses the 'opioid epidemic'. Mgt hopes to partner the drug by YE. We believe '181 could bring significant value (modeling 30% royalties and $250M+ in milestones) to the company as early as 2020. With this asset now unencumbered, NKTR now fits our M&A thesis." (3/21/2017)

Who are some of Nektar Therapeutics' key competitors?

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the folowing people:

  • Robert B. Chess, Independent Chairman of the Board (Age 60)
  • Howard W. Robin, President, Chief Executive Officer, Director (Age 64)
  • Gilbert M. Labrucherie J.D., Chief Financial Officer, Senior Vice President (Age 45)
  • John L. Nicholson, Chief Operating Officer, Senior Vice President (Age 65)
  • Jillian B. Thomsen, Senior Vice President - Finance, Chief Accounting Officer (Age 51)
  • Jonathan Zalevsky, Senior Vice President - Research , Chief Scientific Officer
  • Stephen K. Doberstein Ph.D., Senior Vice President, Research & Development and Chief Research & Development Officer (Age 58)
  • Ivan Philip Gergel M.D., Senior Vice President - Drug Development & Chief Medical Officer (Age 56)
  • Maninder Hora Ph.D., Senior Vice President - Pharmaceutical Development and Manufacturing Operations (Age 63)
  • Mary Tagliaferri M.D., Senior Vice President - Clinical Development and Chief Medical Officer (Age 47)

Who owns Nektar Therapeutics stock?

Nektar Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.61%), OppenheimerFunds Inc. (9.27%), Bank of New York Mellon Corp (1.25%), First Trust Advisors LP (1.08%), Geode Capital Management LLC (0.92%) and Bridger Management LLC (0.87%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

Who sold Nektar Therapeutics stock? Who is selling Nektar Therapeutics stock?

Nektar Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Bridger Management LLC, Deutsche Bank AG, Tamarack Advisers LP, Systematic Financial Management LP, J. Goldman & Co LP, Rice Hall James & Associates LLC and UBS Asset Management Americas Inc.. Company insiders that have sold Nektar Therapeutics company stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

Who bought Nektar Therapeutics stock? Who is buying Nektar Therapeutics stock?

Nektar Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., BlackRock Inc., Public Employees Retirement Association of Colorado, Teachers Advisors LLC, Jennison Associates LLC, Amundi Pioneer Asset Management Inc. and Arizona State Retirement System. Company insiders that have bought Nektar Therapeutics stock in the last two years include R Scott Greer and Roy A Whitfield. View Insider Buying and Selling for Nektar Therapeutics.

How do I buy Nektar Therapeutics stock?

Shares of Nektar Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of Nektar Therapeutics stock can currently be purchased for approximately $83.45.

How big of a company is Nektar Therapeutics?

Nektar Therapeutics has a market capitalization of $13.38 billion and generates $165.44 million in revenue each year. The biopharmaceutical company earns $-153,520,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Nektar Therapeutics employs 468 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]


MarketBeat Community Rating for Nektar Therapeutics (NKTR)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  374 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  536
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nektar Therapeutics (NASDAQ:NKTR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.922.922.922.90
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $48.18$48.18$36.64$26.33
Price Target Upside: 36.32% downside32.70% downside18.46% downside42.96% upside

Nektar Therapeutics (NASDAQ:NKTR) Consensus Price Target History

Price Target History for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018MizuhoReiterated RatingBuy$89.00MediumView Rating Details
1/16/2018Jefferies GroupBoost Price TargetBuy$2.12 -> $88.00HighView Rating Details
1/10/2018Canaccord GenuityReiterated RatingBuy$50.00 -> $80.00LowView Rating Details
11/15/2017Canaccord Genuity GroupBoost Price TargetBuy$35.00 -> $50.00N/AView Rating Details
11/13/2017Roth CapitalSet Price TargetBuy$45.00N/AView Rating Details
11/13/2017JPMorgan Chase & Co.Reiterated RatingPositive -> Buy$44.00N/AView Rating Details
11/7/2017CowenInitiated CoverageOutperformN/AView Rating Details
8/17/2017Evercore ISIInitiated CoverageIn -> In-Line$20.00HighView Rating Details
8/7/2017HC WainwrightInitiated CoverageBuy -> Buy$31.00LowView Rating Details
7/18/2017William BlairReiterated RatingOutperformLowView Rating Details
5/10/2017AegisReiterated RatingBuy$27.00HighView Rating Details
4/11/2017Piper Jaffray CompaniesReiterated RatingOverweight$29.00LowView Rating Details
3/21/2017BTIG ResearchBoost Price TargetPositive$22.00 -> $27.00MediumView Rating Details
9/30/2016Brean CapitalReiterated RatingBuy$23.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Nektar Therapeutics (NASDAQ:NKTR) Earnings History and Estimates Chart

Earnings by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ NKTR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.33)N/AView Earnings Details
11/7/2017Q3 2017$0.21$0.37$126.50 million$152.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.35)($0.39)$33.64 million$34.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.40)($0.42)$29.43 million$24.73 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.28)$40.83 million$37.45 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.32)$32.42 million$36.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.36)$34.17 million$32.77 millionViewListenView Earnings Details
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details
11/5/2015Q315($0.30)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details
7/31/2014Q214($0.38)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details
5/7/2014Q114($0.35)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.45)($0.46)ViewN/AView Earnings Details
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details
3/1/2011Q4 2010($0.16)($0.11)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.05)($0.09)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.09)($0.01)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.09)($0.07)ViewN/AView Earnings Details
3/2/2010Q4 2009$0.08($0.08)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.40)($0.33)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.42)($0.35)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.41)($0.34)ViewN/AView Earnings Details
2/24/2009Q4 2008($0.31)($0.46)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.29)($0.40)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.31)($0.36)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.27)($0.44)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.25)($0.13)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Nektar Therapeutics (NASDAQ:NKTR) Earnings Estimates

2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.32)($0.12)($0.22)
Q2 20182($0.32)($0.13)($0.23)
Q3 20182($0.33)($0.13)($0.23)
Q4 20181($0.33)($0.33)($0.33)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Nektar Therapeutics (NASDAQ:NKTR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Nektar Therapeutics (NASDAQ NKTR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.44%
Institutional Ownership Percentage: 96.23%
Insider Trades by Quarter for Nektar Therapeutics (NASDAQ:NKTR)
Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ NKTR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Gil M. LabrucherieCFOSell3,477$82.94$288,382.38View SEC Filing  
2/16/2018Howard W RobinCEOSell12,788$82.94$1,060,636.72237,147View SEC Filing  
2/16/2018Jillian B. ThomsenCAOSell2,545$82.94$211,082.30View SEC Filing  
2/16/2018John NicholsonCOOSell4,879$82.94$404,664.26387,657View SEC Filing  
2/16/2018Stephen K DobersteinSVPSell2,426$82.94$201,212.4467,394View SEC Filing  
1/22/2018Howard W RobinCEOSell83,333$75.82$6,318,308.06333,268View SEC Filing  
1/2/2018Christopher A KueblerDirectorSell30,000$58.66$1,759,800.0070,500View SEC Filing  
12/13/2017Howard W RobinCEOSell83,333$55.69$4,640,814.77272,768View SEC Filing  
11/13/2017John NicholsonCOOSell15,910$37.78$601,079.80249,066View SEC Filing  
11/8/2017Stephen K DobersteinSVPSell396,323$29.00$11,493,367.0052,016View SEC Filing  
11/6/2017Maninder HoraSVPSell5,117$25.07$128,283.1952,016View SEC Filing  
11/1/2017Howard W RobinCEOSell83,334$23.57$1,964,182.38235,838View SEC Filing  
10/9/2017Howard W RobinCEOSell83,333$24.20$2,016,658.60View SEC Filing  
10/5/2017Stephen K DobersteinSVPSell43,677$24.97$1,090,614.69View SEC Filing  
10/2/2017Gil M. LabrucherieCFOSell120,000$24.45$2,934,000.00View SEC Filing  
10/2/2017Ivan P GergelSVPSell100,000$24.14$2,414,000.0084,871View SEC Filing  
9/22/2017Christopher A KueblerDirectorSell4,000$21.86$87,440.0040,500View SEC Filing  
9/21/2017Robert ChessDirectorSell6,400$21.72$139,008.00274,223View SEC Filing  
9/6/2017Howard W RobinCEOSell83,333$21.54$1,794,992.82235,837View SEC Filing  
8/16/2017Howard W RobinCEOSell91,714$19.26$1,766,411.64152,504View SEC Filing  
8/16/2017Jillian B. ThomsenCAOSell2,648$19.32$51,159.36View SEC Filing  
8/16/2017John NicholsonCOOSell3,177$19.32$61,379.64224,066View SEC Filing  
8/16/2017Stephen K DobersteinSVPSell1,701$19.32$32,863.3231,102View SEC Filing  
8/10/2017Roy A WhitfieldDirectorBuy35,000$17.95$628,250.00133,000View SEC Filing  
7/18/2017Ivan P GergelSVPSell54,920$21.10$1,158,812.0098,492View SEC Filing  
7/14/2017Lutz LingnauDirectorSell30,000$20.76$622,800.0053,450View SEC Filing  
7/12/2017Ivan P GergelSVPSell45,080$21.08$950,286.4051,961View SEC Filing  
7/11/2017Ivan P GergelSVPSell8,389$21.04$176,504.5651,961View SEC Filing  
5/16/2017Gil M. LabrucherieCFOSell3,179$19.55$62,149.45View SEC Filing  
5/16/2017Howard W RobinCEOSell8,388$19.55$163,985.40160,884View SEC Filing  
5/16/2017John NicholsonCOOSell3,146$19.55$61,504.30178,943View SEC Filing  
5/16/2017Stephen K DobersteinSVPSell1,701$19.55$33,254.5532,803View SEC Filing  
5/15/2017Robert ChessDirectorSell5,000$19.79$98,950.00276,623View SEC Filing  
4/17/2017Robert ChessDirectorSell5,000$18.72$93,600.00276,623View SEC Filing  
4/7/2017Lutz LingnauDirectorSell7,000$20.05$140,350.0023,450View SEC Filing  
4/5/2017Christopher A KueblerDirectorSell15,000$21.88$328,200.0050,500View SEC Filing  
4/5/2017Maninder HoraSVPSell180,000$21.70$3,906,000.00View SEC Filing  
3/20/2017Jillian B. ThomsenSVPSell112,500$19.69$2,215,125.00View SEC Filing  
3/3/2017Gil M. LabrucherieCFOSell200,000$15.16$3,032,000.00View SEC Filing  
2/16/2017Gil M. LabrucherieCFOSell2,359$13.14$30,997.26View SEC Filing  
2/16/2017Howard W RobinCEOSell8,636$13.14$113,477.04169,272View SEC Filing  
2/16/2017Ivan P GergelSVPSell1,457$13.14$19,144.9845,022View SEC Filing  
2/16/2017John NicholsonCOOSell3,237$13.14$42,534.18182,089View SEC Filing  
2/8/2017Howard W RobinCEOSell87,500$13.04$1,141,000.00265,408View SEC Filing  
2/3/2017John NicholsonCOOSell75,000$12.39$929,250.00206,821View SEC Filing  
1/17/2017Howard W RobinCEOSell87,500$12.35$1,080,625.00265,408View SEC Filing  
11/17/2016Howard W RobinCEOSell93,458$13.88$1,297,197.04122,908View SEC Filing  
10/24/2016R Scott GreerDirectorBuy15,000$13.50$202,500.00121,333View SEC Filing  
10/4/2016Howard W. RobinCEOSell87,500$17.06$1,492,750.00View SEC Filing  
9/16/2016Christopher A. KueblerDirectorSell7,500$19.13$143,475.00View SEC Filing  
9/15/2016Robert ChessDirectorSell12,000$19.21$230,520.00View SEC Filing  
9/1/2016Howard W. RobinCEOSell87,500$17.83$1,560,125.00View SEC Filing  
8/16/2016Gil M. LabrucherieCFOSell3,305$17.56$58,035.80View SEC Filing  
8/16/2016Howard W. RobinCEOSell11,817$17.56$207,506.52View SEC Filing  
8/16/2016John NicholsonCOOSell3,317$17.56$58,246.52View SEC Filing  
8/16/2016Stephen K. DobersteinSVPSell1,336$17.56$23,460.16View SEC Filing  
8/1/2016Robert ChessDirectorSell5,000$17.26$86,300.00View SEC Filing  
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00106,809View SEC Filing  
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.888,757View SEC Filing  
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.6019,103View SEC Filing  
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.927,033View SEC Filing  
5/17/2016John NicholsonCFOSell856$13.58$11,624.4878,486View SEC Filing  
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.0031,450View SEC Filing  
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.2413,478View SEC Filing  
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.725,158View SEC Filing  
2/17/2016Maninder HoraSVPSell963$11.92$11,478.965,803View SEC Filing  
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.345,251View SEC Filing  
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.3410,000View SEC Filing  
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.003,999View SEC Filing  
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.0016,450View SEC Filing  
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.045,251View SEC Filing  
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.0410,000View SEC Filing  
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.003,999View SEC Filing  
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.0020,000View SEC Filing  
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.875,251View SEC Filing  
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.8710,000View SEC Filing  
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.003,999View SEC Filing  
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.0020,000View SEC Filing  
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.004,751View SEC Filing  
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.0010,000View SEC Filing  
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.003,499View SEC Filing  
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.0016,450View SEC Filing  
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.004,751View SEC Filing  
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.0010,000View SEC Filing  
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.003,499View SEC Filing  
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.964,751View SEC Filing  
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.9610,000View SEC Filing  
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.003,499View SEC Filing  
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.0020,000View SEC Filing  
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Nektar Therapeutics (NASDAQ NKTR) News Headlines

Source:
DateHeadline
Nektar Therapeutics (NKTR) Upgraded to "Hold" by Zacks Investment ResearchNektar Therapeutics (NKTR) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - February 21 at 2:11 PM
Nektar Therapeutics (NKTR) Given Consensus Recommendation of "Buy" by AnalystsNektar Therapeutics (NKTR) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 21 at 11:50 AM
Nektar Therapeutics (NKTR) CAO Sells $211,082.30 in StockNektar Therapeutics (NKTR) CAO Sells $211,082.30 in Stock
www.americanbankingnews.com - February 20 at 9:30 PM
Insider Selling: Nektar Therapeutics (NKTR) CFO Sells 3,477 Shares of StockInsider Selling: Nektar Therapeutics (NKTR) CFO Sells 3,477 Shares of Stock
www.americanbankingnews.com - February 20 at 9:30 PM
Stephen K. Doberstein Sells 2,426 Shares of Nektar Therapeutics (NKTR) StockStephen K. Doberstein Sells 2,426 Shares of Nektar Therapeutics (NKTR) Stock
www.americanbankingnews.com - February 20 at 9:30 PM
Nektar Therapeutics (NKTR) COO John Nicholson Sells 4,879 SharesNektar Therapeutics (NKTR) COO John Nicholson Sells 4,879 Shares
www.americanbankingnews.com - February 20 at 9:30 PM
Nektar Therapeutics (NKTR) CEO Sells $1,060,636.72 in StockNektar Therapeutics (NKTR) CEO Sells $1,060,636.72 in Stock
www.americanbankingnews.com - February 20 at 9:12 PM
Can Bristol-Myers Squibb Squeeze $3.6 Billion From Its Nektar ... - Motley FoolCan Bristol-Myers Squibb Squeeze $3.6 Billion From Its Nektar ... - Motley Fool
www.fool.com - February 20 at 3:34 PM
Can Bristol-Myers Squibb Squeeze $3.6 Billion From Its Nektar Therapeutics Deal?Can Bristol-Myers Squibb Squeeze $3.6 Billion From Its Nektar Therapeutics Deal?
www.fool.com - February 20 at 9:31 AM
Nektar Therapeutics (NKTR) Scheduled to Post Earnings on TuesdayNektar Therapeutics (NKTR) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:12 AM
Bristol-Myers Squibb Looks For Growth Of Opdivo Beyond ... - Seeking AlphaBristol-Myers Squibb Looks For Growth Of Opdivo Beyond ... - Seeking Alpha
seekingalpha.com - February 16 at 3:37 PM
Bristol-Myers and Nektar Therapeutics to jointly develop cancer treatments - MarketWatchBristol-Myers and Nektar Therapeutics to jointly develop cancer treatments - MarketWatch
www.marketwatch.com - February 16 at 3:37 PM
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised)Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised)
finance.yahoo.com - February 16 at 9:59 AM
Recent BMY NewsRecent BMY News
www.bloomberg.com - February 15 at 3:39 PM
Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR) agree to at develop and commercialize the combinations of NKTR-214 and Opdivo (nivolumab) anBristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR) agree to at develop and commercialize the combinations of NKTR-214 and Opdivo (nivolumab) an
seekingalpha.com - February 15 at 3:39 PM
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives StockNektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock
finance.yahoo.com - February 15 at 3:39 PM
Nektar (NKTR) Surges: Stock Moves 11% HigherNektar (NKTR) Surges: Stock Moves 11% Higher
finance.yahoo.com - February 15 at 3:39 PM
AMAG Gets FDA Nod, ABMD Hits All-time High, GLMDs NAFLD Trial Flops, NKTR Abuzz - NasdaqAMAG Gets FDA Nod, ABMD Hits All-time High, GLMD's NAFLD Trial Flops, NKTR Abuzz - Nasdaq
www.nasdaq.com - February 15 at 5:34 AM
Nektar Therapeutics: What The Bristol-Myers Squibb Deal For NKTR-214 Entails - Seeking AlphaNektar Therapeutics: What The Bristol-Myers Squibb Deal For NKTR-214 Entails - Seeking Alpha
seekingalpha.com - February 15 at 5:34 AM
This Megadeal Caused Nektar Therapeutics' 11% Spike TodayThis Megadeal Caused Nektar Therapeutics' 11% Spike Today
finance.yahoo.com - February 15 at 5:34 AM
This Megadeal Caused Nektar Therapeutics 11% Spike TodayThis Megadeal Caused Nektar Therapeutics' 11% Spike Today
www.fool.com - February 14 at 7:07 PM
Bristol-Myers signs record biotech partnership dealBristol-Myers signs record biotech partnership deal
www.ft.com - February 14 at 3:19 PM
Nektars $2.8 Billion Licensing Pact Leaves Options OpenNektar's $2.8 Billion Licensing Pact Leaves Options Open
www.bloomberg.com - February 14 at 3:19 PM
Bristol-Myers and Nektar Therapeutics team up to develop cancer combination treatments across nine tumor types; Nektar down 5% premarketBristol-Myers and Nektar Therapeutics team up to develop cancer combination treatments across nine tumor types; Nektar down 5% premarket
seekingalpha.com - February 14 at 3:19 PM
Why Bristol-Myers Squibb just made a $1.85 billion bet on a cancer drugWhy Bristol-Myers Squibb just made a $1.85 billion bet on a cancer drug
www.businessinsider.com - February 14 at 3:19 PM
Bristol-Myers to pay $1.85 billion in cancer deal with NektarBristol-Myers to pay $1.85 billion in cancer deal with Nektar
finance.yahoo.com - February 14 at 3:19 PM
Bristol-Myers to pay $1.85 bln in cancer deal with NektarBristol-Myers to pay $1.85 bln in cancer deal with Nektar
finance.yahoo.com - February 14 at 3:19 PM
[$$] Bristol-Myers Squibb, Nektar to Partner on Cancer Therapy[$$] Bristol-Myers Squibb, Nektar to Partner on Cancer Therapy
finance.yahoo.com - February 14 at 3:19 PM
This Biotech Stock Rocketed On An Immuno-Oncology Tie With BristolThis Biotech Stock Rocketed On An Immuno-Oncology Tie With Bristol
finance.yahoo.com - February 14 at 3:19 PM
Nektar Gets a Payday But No Mega-BuyoutNektar Gets a Payday But No Mega-Buyout
finance.yahoo.com - February 14 at 3:19 PM
Bristol-Myers inks $1.85 billion cancer drug dealBristol-Myers inks $1.85 billion cancer drug deal
finance.yahoo.com - February 14 at 3:19 PM
Tech Shines as Fading Inflation Fears Boost StocksTech Shines as Fading Inflation Fears Boost Stocks
finance.yahoo.com - February 14 at 3:19 PM
Nektar Shares Surge on Bristol-Myers CollaborationNektar Shares Surge on Bristol-Myers Collaboration
finance.yahoo.com - February 14 at 3:19 PM
Nektar Therapeutics (NKTR) Stock Rating Reaffirmed by MizuhoNektar Therapeutics (NKTR) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - February 14 at 12:10 PM
$35.81 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter$35.81 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter
www.americanbankingnews.com - February 12 at 6:02 AM
Nektar Therapeutics (NKTR) Rating Lowered to Buy at BidaskClubNektar Therapeutics (NKTR) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - February 11 at 9:10 PM
Nektar Therapeutics (NKTR) Expected to Announce Earnings of -$0.35 Per ShareNektar Therapeutics (NKTR) Expected to Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - February 10 at 9:44 AM
Heres What Was Behind Nektar Therapeutics Stupendous 40% Jump in JanuaryHere's What Was Behind Nektar Therapeutics Stupendous 40% Jump in January
www.msn.com - February 9 at 5:31 AM
OppenheimerFunds Big Biotech Stock Buys - BarronsOppenheimerFunds' Big Biotech Stock Buys - Barron's
www.barrons.com - February 8 at 5:16 AM
Heres What Was Behind Nektar Therapeutics Stupendous 40% Jump in January - Motley FoolHere's What Was Behind Nektar Therapeutics Stupendous 40% Jump in January - Motley Fool
www.fool.com - February 8 at 5:16 AM
[$$] OppenheimerFunds Big Biotech Stock Buys[$$] OppenheimerFunds' Big Biotech Stock Buys
finance.yahoo.com - February 8 at 5:16 AM
Here's What Was Behind Nektar Therapeutics Stupendous 40% Jump in JanuaryHere's What Was Behind Nektar Therapeutics Stupendous 40% Jump in January
finance.yahoo.com - February 8 at 5:16 AM
This Explains Why Alkermes Plc Is Falling Today - Motley FoolThis Explains Why Alkermes Plc Is Falling Today - Motley Fool
www.fool.com - February 6 at 5:25 AM
Here’s Why Alkermes Plc Is Moving NowHere’s Why Alkermes Plc Is Moving Now
finance.yahoo.com - February 5 at 3:17 PM
Nektar Therapeutics Weighs Options Including Sale - BloombergNektar Therapeutics Weighs Options Including Sale - Bloomberg
www.bloomberg.com - February 4 at 5:31 AM
UPDATE: Nektar Therapeutics (NKTR) Said to Explore Options Including Sale - BloombergUPDATE: Nektar Therapeutics (NKTR) Said to Explore Options Including Sale - Bloomberg
www.streetinsider.com - February 3 at 5:31 AM
Biotech Firm Nektar Therapeutics Explores Partnership OptionsBiotech Firm Nektar Therapeutics Explores Partnership Options
finance.yahoo.com - February 3 at 5:31 AM
Contrasting Nektar Therapeutics (NKTR) & Heron Therapeutics (HRTX)Contrasting Nektar Therapeutics (NKTR) & Heron Therapeutics (HRTX)
www.americanbankingnews.com - February 2 at 11:30 PM
UPDATE: Nektar Therapeutics (NKTR) Said to Explore Options Including Sale - Bloomberg - StreetInsider.comUPDATE: Nektar Therapeutics (NKTR) Said to Explore Options Including Sale - Bloomberg - StreetInsider.com
www.streetinsider.com - February 2 at 3:18 PM
Noteworthy Thursday Option Activity: MDP, NKTR, DPZ - NasdaqNoteworthy Thursday Option Activity: MDP, NKTR, DPZ - Nasdaq
www.nasdaq.com - February 2 at 5:28 AM

SEC Filings

Nektar Therapeutics (NASDAQ:NKTR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nektar Therapeutics (NASDAQ:NKTR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nektar Therapeutics (NASDAQ NKTR) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.